SH PHARMA (02607.HK) announced that on December 31 of last year, it entered into a share transfer agreement with Hutchison Invest. It is reported that SH PHARMA agreed to acquire a 10% stake in "Shanghai Hutchison Pharmaceuticals" from Hutchison Invest for approximately 0.995 billion yuan.

On the same day, SH PHARMA's independent third party, Jinpu Healthcare, entered into a share transfer agreement with Hutchison Invest. It is reported that Jinpu Healthcare or its designated entity will acquire a 35% stake in "Shanghai Hutchison Pharmaceuticals" from Hutchison Invest. As of yesterday (1st), the ownership of Shanghai Hutchison Pharmaceuticals was held by Hutchison Invest and SH PHARMA's wholly-owned subsidiary, Shanghai Pharmaceuticals, with each holding 50% of the shares.

Upon completion of the acquisition, "Shanghai Hutchison Pharmaceuticals" will be directly and indirectly held 60% by SH PHARMA and will become a non-wholly owned subsidiary of the company. Its financial performance will be consolidated into the group's consolidated financial statements. (js/w)

~